Third-line therapy for chronic myeloid leukemia: current status and future directions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Third-line therapy for chronic myeloid leukemia: current status and future directions
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-19
DOI
10.1186/s13045-021-01055-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
- (2020) Qian Jiang et al. BLOOD
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Novel therapeutic approaches in chronic myeloid leukemia
- (2020) Nurgül Özgür Yurttaş et al. LEUKEMIA RESEARCH
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
- (2020) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
- (2020) Yasmin Abaza et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
- (2020) Andreas Hochhaus et al. BLOOD
- Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Chronic myeloid leukemia stem cells
- (2019) Mohammad Houshmand et al. LEUKEMIA
- Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
- (2019) Valentín García-Gutiérrez et al. Frontiers in Oncology
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
- (2019) Peter E. Westerweel et al. Frontiers in Oncology
- BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
- (2019) Federica Loscocco et al. Frontiers in Oncology
- PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
- (2019) Anna G. Turkina et al. BLOOD
- Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
- (2019) B. Douglas Smith et al. BLOOD
- Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy
- (2019) Jorge E. Cortes et al. BLOOD
- Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
- (2019) Fabien Muselli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
- (2018) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
- (2018) Michele Massimino et al. Molecular Cancer
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
- (2018) Maro Ohanian et al. Lancet Haematology
- Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
- (2018) Kendra Sweet et al. LEUKEMIA RESEARCH
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
- (2016) Hanna J. Khoury et al. Clinical Lymphoma Myeloma & Leukemia
- A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
- (2016) Moussab Damlaj et al. Expert Opinion On Drug Safety
- Targeting the mTOR Pathway in Leukemia
- (2016) Shira Dinner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors
- (2016) Abhishek Maiti et al. LEUKEMIA & LYMPHOMA
- Chronic myeloid leukemia: Second-line drugs of choice
- (2015) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
- (2015) Jorge E. Cortes et al. CANCER
- Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience
- (2015) BF Ribeiro et al. Clinics
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
- (2015) Bing Z. Carter et al. Oncotarget
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
- (2014) H. Herrmann et al. BLOOD
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
- (2014) A A Mian et al. LEUKEMIA
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
- (2013) Xiaomei Ren et al. JOURNAL OF MEDICINAL CHEMISTRY
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
- (2012) A. R. Rossi et al. HAEMATOLOGICA
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
- (2012) D J DeAngelo Blood Cancer Journal
- Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis
- (2011) Yukio Kobayashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
- (2010) A. R. Ibrahim et al. BLOOD
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
- (2010) Bin Zhang et al. CANCER CELL
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
- (2010) F J Giles et al. LEUKEMIA
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Stem Cell Transplant for Chronic Myeloid Leukemia in the Imatinib Era
- (2010) Jerald Radich SEMINARS IN HEMATOLOGY
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
- (2009) R. J. Garg et al. BLOOD
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation